Kiniksa Pharmaceuticals International, plc
KNSA- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001730430
In the last 90 days, Kiniksa Pharmaceuticals International, plc insiders filed 0 open-market purchases and 7 sales; 266 institutions reported holding it in 13F filings for Q2 2026, worth $2.99B in total; no superinvestor holds it.
Key figures
- Market capNo recent share count in SEC filings
- –
- Insider buysOpen market, last 90 days
- 0
- Insider sellsLast 90 days, $77.5M in total
- 7
- 13F holdersQ2 2026, +43 vs. previous quarter
- 266
- 13F valueReported value at the end of Q2 2026
- $2.99B
- Superinvestors holdingAt the end of Q2 2026
- 0
Price chart
Financials
See financial statementsFrom SEC filings, in USD.
- Revenue, FY2025
- $677.6M
- +60.1% year over year
- Net income, FY2025
- $59.0M
- No comparable prior period
- Free cash flow, FY2025
- $136.4M
- +436.8% year over year
- Revenue, Q3 FY2026
- $286.0M
- +58.1% year over year
Revenue flow, FY2025
Green is profit; orange is costs, expenses and taxes. Percentages are shares of revenue.
Short interest
See short dataFrom FINRA, settlement date Oct 30, 2026.
- Short interest
- 4.29M
- Shares sold short
- Change
- +531.1K
- +14.1% vs. previous
- Days to cover
- 3.89
- At average daily volume
Superinvestors holding KNSA, Q2 2026
Go to the superinvestors tabNo superinvestor reported holding KNSA at the end of Q2 2026.
Latest insider trades
See all insider tradesOpen-market purchases and sales by Kiniksa Pharmaceuticals International, plc insiders from Form 4, newest first.
| Filed (ET) | Trade date | Filing delay | Insider | Transaction | Shares | Avg price | Value | Holding change | Flags |
|---|---|---|---|---|---|---|---|---|---|
| Nov 6, 2026 (view filing)4:52 PM ET | Nov 4 | 2 days | Patel Sanj KCHAIRMAN & CEO | SSaleClass A Ordinary Share | −151.3K | $94.71 | −$14.3M | −16.3%774.5K after | 5 lots10b5-1 |
| Nov 3, 2026 (view filing)7:30 PM ET | Oct 30-Nov 3 | 4 days | Patel Sanj KCHAIRMAN & CEO | SSaleClass A Ordinary Share | −402.5K | $92.92 | −$37.4M | −34.0%780.0K after | 15 lots10b5-1 |
| Nov 3, 2026 (view filing)6:32 PM ET | Nov 2 | 1 day | Ragosa MarkCHIEF FINANCIAL OFFICER | SSaleClass A Ordinary Share | −36.8K | $92.16 | −$3.39M | −63.8%20.9K after | 4 lots10b5-1 |
| Nov 3, 2026 (view filing)6:28 PM ET | Oct 30-Nov 2 | 4 days | Paolini John F.CHIEF MEDICAL OFFICER | SSaleClass A Ordinary Share | −96.0K | $93.09 | −$8.94M | −57.9%69.9K after | 10 lots10b5-1 |
| Nov 3, 2026 (view filing)6:27 PM ET | Oct 30-Nov 2 | 4 days | Moat RossCHIEF OPERATING OFFICER | SSaleClass A Ordinary Share | −103.6K | $92.93 | −$9.63M | −91.0%10.3K after | 11 lots10b5-1 |
| Nov 3, 2026 (view filing)6:26 PM ET | Oct 30 | 4 days | Megna Michael RCHIEF ACCOUNTING OFFICER | SSaleClass A Ordinary Share | −36.3K | $94.43 | −$3.42M | −74.1%12.7K after | 7 lots10b5-1 |
| Sep 3, 2026 (view filing)4:40 PM ET | Sep 3 | Same day | Megna Michael RCHIEF ACCOUNTING OFFICER | SSaleClass A Ordinary Share | −4.60K | $80.30 | −$369.4K | −13.7%29.1K after | 10b5-1 |
| Jul 31, 2026 (view filing)4:34 PM ET | Jul 29 | 2 days | Cole G BradleyDirector | SSaleClass A Ordinary Share | −3.67K | $81.43 | −$299.1K | −23.9%11.7K after | |
| May 5, 2026 (view filing) | May 1 | 4 days | Paolini John F.CHIEF MEDICAL OFFICER | SSaleClass A Ordinary Share | −58.4K | $53.71 | −$3.14M | −47.1%65.6K after | 2 lots10b5-1 |
| May 1, 2026 (view filing) | May 1 | Same day | Patel Sanj KCHAIRMAN & CEO | SSaleClass A Ordinary Share | −48.6K | $54.02 | −$2.62M | −100.0%0 after | 10b5-1 |
Top 10 13F holders, Q2 2026
See all 266 holdersThe largest institutional positions in Kiniksa Pharmaceuticals International, plc at the end of Q2 2026; share changes are against Q1 2026.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| FMR LLC | 6,971,361 | $445.8M | 0.02% | +147,661+2.2% | Added |
| Rubric Capital Management LP | 3,999,800 | $255.8M | 2.35% | +249,800+6.7% | Added |
| Baker Bros. Advisors LP | 2,834,643 | $181.3M | 0.91% | +8,397+0.3% | Added |
| BlackRock, Inc. | 2,739,615 | $175.2M | 0.00% | +2,252,878+462.9% | Added |
| Tang Capital Management LLC | 2,259,889 | $144.5M | 6.56% | 00.0% | Unchanged |
| Vanguard Portfolio Management LLC | 1,911,335 | $122.2M | 0.01% | +145,067+8.2% | Added |
| Vanguard Capital Management LLC | 1,360,840 | $87.0M | 0.00% | +27,747+2.1% | Added |
| Morgan Stanley | 1,011,143 | $64.7M | 0.00% | +13,357+1.3% | Added |
| Arrowstreet Capital, Limited Partnership | 957,514 | $61.2M | 0.03% | +64,848+7.3% | Added |
| Spruce Street Capital LP | 918,070 | $58.7M | 11.52% | +157,007+20.6% | Added |
Holders of 5% or more of KNSA
See all 5 holders and filingsHolders whose latest Schedule 13D or 13G filing reports 5% or more of Kiniksa Pharmaceuticals International, plc.
| Holder | Latest form | Stake | Change | First filed | Latest filing | Filing |
|---|---|---|---|---|---|---|
| FMR LLC | 13G/A | 14.80%6.79M shares | +4.20 ppfrom 10.60% | Mar 6, 20262 filings | May 6, 2026 | SEC |
| Rubric Capital Management LP | 13G/A | 7.37%3.33M shares | −1.87 ppfrom 9.24% | Feb 12, 20245 filings | Feb 13, 2026 | SEC |
| Baker Bros. Advisors LP | 13D/A | 7.00%3.25M shares | – | Oct 8, 20242 filings | May 26, 2026 | SEC |
| BlackRock, Inc. | 13G | 5.50%2.53M shares | +4.50 ppfrom 1.00% | Oct 21, 20245 filings | Jul 29, 2026 | SEC |
| Tang Capital Management LLC | 13G | 5.20%2.18M shares | New | Apr 4, 20251 filing | Apr 4, 2025 | SEC |